EGFR and neoplasm: Based on these advantages, increasing studies have been reported on tumor-specific mutations in circulating exoDNA, such as EGFR mutations in lung adenocarcinoma patients and KRAS mutations in pancreatic cancer patients.9,11,15 However, no studies have been reported on the detection of tumor-specific mutations in circulating exoDNA in HCC patients.